Caplin Point Laboratories Stock Analysis

Caplin Point Laboratories Limited is an Indian pharmaceutical company that started in 1990. The company makes a wide range of medicines, such as tablets, capsules, creams, ointments, injections, and syrups. Caplin Point focuses on providing affordable and high-quality healthcare products, especially to developing countries in Latin America, Southeast Asia, and Africa. The company also produces important ingredients used in medicines and offers services to other pharmaceutical companies. Caplin Point is known for its strong research and development, which helps it create new and better medicines. Its main goal is to make essential healthcare products easily available to people who need them most.

Company Insights
The company has a market capitalization of 15,421 crores
The share price of the company is 2,029
The book value of the company is 375
The company's debt-to-equity ratio is 0.00
The company's annual dividend yield is 0.23%
The company's stock P/E is 28.8
The earnings per share are 70.6
The company's ROCE is 25.8%

Financial Report
The company's sales in the last 5 years
Sales in 2021 is 1,061 crores
Sales in 2022 is 1,269 crores
Sales in 2023 is 1,467 crores
Sales in 2024 is 1,694 crores
Sales in 2025 is 1,937 crores

The company's profit in the last 5 years
Profit in 2021 is 251 crores
Profit in 2022 is 308 crores
Profit in 2023 is 377 crores
Profit in 2024 is 461 crores
Profit in 2025 is 541 crores

Sales & Profit Growth
The company's sales growth in the last 5 years
Sales growth in the last 5 years is 17.6%
Sales growth in the last 3 years is 15.1%
Sales growth in the last 1 year is 14.4%

The company's profit growth in the last 5 years
Profit growth in the last 5 years is 20.5%
Profit growth in the last 3 years is 21.5%
Profit growth in the last 1 year is 17.6%

Holdings
Promoters are 70.56%
FIIs are 5.73%
DIIs are 2.00%
Public are 21.72%

Company News

• Caplin Point Laboratories Limited, a leading Indian pharmaceutical company, has recently secured approval from the United States Food and Drug Administration (USFDA) for its Haloperidol Decanoate Injection. This significant regulatory milestone was officially announced in May 2025 and marks a key advancement for the company in expanding its sterile injectable product portfolio in the global market.

• The approval underscores Caplin Point’s commitment to high-quality manufacturing standards and its strategic focus on sterile injectables, which are critical in psychiatric and neurological treatments. This achievement is expected to enhance the company’s presence in regulated markets, including the US, and strengthen its position in emerging markets where it already has a strong footprint.

• In addition to this, Caplin Point continues to demonstrate robust financial performance, with a market capitalization of over ₹15,000 crore and consistent profit growth. The company has also reduced its debt significantly, maintaining a healthy balance sheet and strong return ratios, which support its ongoing investment in research and development.

• Looking ahead, Caplin Point plans to file its first GLP-1 product across current emerging markets in the coming quarters and is in discussions with Chinese pharmaceutical players to further expand its global reach. The company’s board is scheduled to meet on May 15, 2025, to review financial results and other strategic initiatives.

• This USFDA approval for Haloperidol Decanoate Injection is a testament to Caplin Point’s growing capabilities and ambition to deliver advanced pharmaceutical solutions worldwide, reinforcing its role as a trusted player in the global healthcare industry.

Technical Analysis

Company Chart

Moving Averages (MA)

• The stock is currently trading near the 50-MA, which indicates that the stock can either go up or down.

• The stock is currently trading near the 200-MA, which also indicates that the stock can either go up or down.

Relative Strength Index (RSI)

Currently, the RSI of the company is 46, which indicates that the stock is neither in the overbought zone nor in the oversold zone.

My Analysis

Caplin Point Laboratories is showing strong financial growth and stability. In the latest quarter ending March 2025, the company achieved its highest-ever net sales of ₹502 crore and a record profit after tax of ₹145 crore. Its operating profit and earnings per share also reached new highs, reflecting effective management and increasing profitability. Over the past year, Caplin Point’s revenue, profit, and margins have steadily improved, with quarterly revenues and profits rising consistently. The company’s financial performance indicates it is well-managed and continues to grow, making it a strong player in the pharmaceutical industry